The expected timeline for the completion of this expansion is five months, and the company expects the enhanced production capacity will be operational by the end of December 2024
Month: August 2024
How Economic Grievances Were Exploited in Britain’s Violent Unrest
Nationalist hatred has been linked to forces like stagnant wages and declining services, even though research shows immigration helps many economies.
Why you probably shouldn’t open a real estate brokerage
The wisest thing you can do is learn from the mistakes of others, especially when it comes to long-term career decisions that are hard to reverse, Mainframe founder and CEO Sean Frank writes.
ENFN Investors Have Opportunity to Join Enfusion, Inc. Securities Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–ENFN Investors Have Opportunity to Join Enfusion, Inc. Securities Fraud Investigation with the Schall Law Firm
Aurobindo Pharma Q1FY25 results: Net profit jumps 61% to Rs 919 cr
Revenue from operations increased to Rs 7,567 crore in the June quarter as against Rs 6,851 crore in the year-ago period, the drug maker said in a statement
Stellantis to Lay Off Up to 2,450 at Ram Truck Plant in Warren, Michigan
The move is the latest sign of trouble for the trans-Atlantic automaker, which has had sluggish North American sales and has said it needs to cut costs.
Banks should bring in innovative products to mobilise deposits: Sitharaman
The banks, she stressed, need to focus on core banking business which is mobilising deposits
すい臓がん患者を対象とした栄養補助食品としてのニチブライトβグルカンについての臨床研究で、有望な結果を国際学会で近森病院の研究グループが報告
東京–(BUSINESS WIRE)–（ビジネスワイヤ） — ニチブライトβグルカンの投与により、すい臓の悪性腫瘍の外科的切除を受けた患者の免疫力が向上し、すい臓がんおよびその再発のバイオマーカーが低下したとの研究結果が、横浜で開催された米国臨床腫瘍学会「ASCO®Breakthrough」で発表されました。二チブライト群では、対照群と比較して、免疫のマーカーであるIgAとCD209が上昇し、すい臓がんのマーカーであるCA19-9とがんの再発及び重症度を示すCD44が有意に低下したことが、高知県にある近森病院の栄養サポートチームと消化器外科医による臨床研究で明らかになりました。ニチブライトの投与後に平均生存期間が改善したことは、非常に重要な成果であると考えられます。 すい臓がんは予後が非常に悪い病気です。アレルゲンフリーであるニチブライトβグルカンには、動物実験において免疫系を改善し腫瘍のサイズを縮小する、また、健康なボランティア、高齢者、がん患者を対象とした臨床試験においてNK細胞の細胞傷害を改善するという、安全性と有効性に関する先行研究のデータがあり、これらのデータが今回の
NNE Investors Have Opportunity to Lead NANO Nuclear Energy Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–NNE Investors Have Opportunity to Lead NANO Nuclear Energy Inc. Securities Fraud Lawsuit with the Schall Law Firm
Rosen Law Firm Urges lululemon athletica inc. (LULU) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of lululemon athletica inc. (NASDAQ: LULU) between December 7, 2023 and July 24, 2024, both dates inclusive (the “Class Period”). Lululemon is a designer, distributor, and retailer of technical athletic apparel, footwear, and accessories. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-365